--- title: "Calidi Biotherapeutics effects 1-for-16 reverse stock split" url: "https://aibio.space/news/calidi-biotherapeutics-effects-1-16-reverse-stock-split/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-07-27" section: "Listings" tickers: "AMEX:CLDI" source: "https://www.sec.gov/Archives/edgar/data/1855485/000149315226035666/form8-k.htm" summary: "The split became effective July 30, 2026, and the common stock began trading split-adjusted on July 31 under the existing CLDI symbol." --- By the aibio.space news desk. Sources - [Calidi Biotherapeutics, Inc. 8-K (2026-07-31)](https://www.sec.gov/Archives/edgar/data/1855485/000149315226035666/form8-k.htm) - [Calidi Biotherapeutics, Inc. 10-K (2026-03-27): business](https://www.sec.gov/Archives/edgar/data/1855485/000149315226013242/form10-k.htm) - [Calidi Biotherapeutics, Inc. financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/1855485/000149315226013242/) [CLDI](https://aibio.space/companies/calidi-biotherapeutics/) 2026-07-27 # Calidi Biotherapeutics effects 1-for-16 reverse stock split Tickers [CLDI](https://aibio.space/companies/calidi-biotherapeutics/) The split became effective July 30, 2026, and the common stock began trading split-adjusted on July 31 under the existing CLDI symbol. ## Key facts - **Company**: Calidi Biotherapeutics, Inc. (AMEX: CLDI) - **News type**: Listings - **Primary source**: [Calidi Biotherapeutics, Inc. 8-K (2026-07-31)](https://www.sec.gov/Archives/edgar/data/1855485/000149315226035666/form8-k.htm) *The Capitol in autumn. CC0, via rawpixel. The picture shows the field, not the companies named.* Calidi Biotherapeutics, Inc. said in a [Form 8-K](https://www.sec.gov/Archives/edgar/data/1855485/000149315226035666/form8-k.htm) that it effected a reverse stock split of its common stock at a ratio of 1-for-16. The split became effective on July 30, 2026. The common stock began trading on a split-adjusted basis at the start of trading on July 31, 2026, under the company's existing symbol, CLDI. Stockholders approved the split at the annual meeting held on June 12, 2026. The filing reports it under Item 3.03 and Item 5.03. ## Why the company did it The company said it effected the split as a proactive measure intended to increase the per-share trading price, support the continued listing of its common stock on NYSE American, and reduce the risk that the stock could become subject to delisting for failing to satisfy the continued listing standards. The company also said it cannot provide assurance that the split will achieve those effects or that, if achieved, they will be sustained. ## The terms The company filed a Certificate of Amendment with the Delaware Secretary of State on July 27, 2026. Each stockholder's shares were exchanged for the number of shares equal to the pre-split shares divided by sixteen, rounded up to the nearest whole share. No fractional shares were issued, and no cash or other consideration was paid for fractions. Equity awards outstanding before the split were adjusted to reflect it. The common stock was assigned a new CUSIP number, 320703 507. The authorized capital did not change. Calidi is authorized to issue 330,000,000 shares of common stock, of which 312,000,000 are designated as voting common stock and 18,000,000 as non-voting common stock, and 1,000,000 shares of preferred stock with a par value of $0.0001. The split had no effect on the par value of the common stock or the preferred stock. Immediately after the split took effect, approximately 2,445,396 shares of common stock and 9,375 shares of non-voting common stock held in escrow were issued and outstanding. The filing says each common stockholder's percentage ownership and proportional voting power remained unchanged, except for minor changes from the treatment of fractional shares. ## Background and finances Calidi's principal executive offices are in San Diego, California. Its annual report, filed March 27, 2026, says it operates in Germany through its wholly owned subsidiary StemVac GmbH. It also says Calidi Biotherapeutics Australia Pty Ltd was formed in October 2022 to operate in Australia for a portion of its planned clinical trial activities for its SNV1 program. The report also says the company is an emerging growth company and a smaller reporting company. For fiscal 2025, Calidi reported research and development expense of $9.7 million, compared with $8.9 million in 2024. It reported a net loss of $19.9 million for 2025 and $22.1 million for 2024. Cash from operations was negative $21.3 million in 2025 and negative $19.7 million in 2024. ## What the split does not change A reverse split lifts the quoted price but does not add cash or equity. Calidi lost $19.9 million in 2025 after $22.1 million in 2024, and it used $21.3 million of cash in operations in 2025. Year-end 2024 cash and cash equivalents were $9.6 million. The filing gives no later cash number and no financing plan. The authorized capital did not change either. The company can issue up to 330,000,000 common shares against approximately 2,445,396 shares outstanding after the split, which leaves wide room for new issuance that would dilute holders. The company itself says it cannot assure that the split will lift the price or keep the listing, so delisting risk remains. Andrew Jackson, Chief Financial Officer, signed the report. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story CLDI Calidi Biotherapeutics, Inc. AMEX ยท United States Open the starter desk ## More in Listings Listings ### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/) Oct 29, 2026 Listings ### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/) Oct 29, 2026 Listings ### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/) Oct 28, 2026 --- Source page: https://aibio.space/news/calidi-biotherapeutics-effects-1-16-reverse-stock-split/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Calidi Biotherapeutics effects 1-for-16 reverse stock split", 2026-07-27, https://aibio.space/news/calidi-biotherapeutics-effects-1-16-reverse-stock-split/